Health Trials

About this trial

Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. This is a feasibility study to assess the acute effect of IRW in egg white hydrolysate for the management of high sugar and blood pressure.

Participants at high risk of type 2 diabetes (T2D) or having T2D will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing different protein powders. Each treatment will be separated by a minimum of 1-week.

Participants in the healthy control group will undergo 1 treatment only (one day).

Eligibility criteria

Qualifiers

Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area/driving distance).

Normal weight (BMI below 25 kg/m2 or Asian population below 23 kg/m2 )

Waist circumference below the following ethnic specific cut offs: Canada / USA: <102 cm men and <88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: <94 cm men and <80 cm women; Asians, Japanese, South and Central Americans: <90 cm men and <80 cm women

Fasting glucose <5.6 mmol/L

Disqualifiers

Individuals with a previous history of CVD, renal disorder, monogenic dyslipidemia, with endocrine disorders other than T2D

Individuals taking chronic anti-inflammatory drugs (including aspirin, antihistamines, and omega-3 supplements)

Pregnant/lactating women

Individuals aged above 70 years

Trial design

Treatments tested in this trial

  • Egg White Powder

Treatment groups

28 Participants
are divided into 4 treatment groups

Locations

1
University of AlbertaT6G 2P5, EdmontonAlberta, Canada

Sponsors and collaborators

University of Alberta

Lead sponsor

Source ClinicalTrials.gov